Table:
Baseline characteristics
| Pancreatic cancer analysis cohort (n=677) | Patients with actionable findings (n=189) |
No marker group (n=488) | ||
|---|---|---|---|---|
| Matched therapy group (n=46) | Unmatched therapy group (n=143) | |||
| Sex | ||||
| Male | 359 (53%) | 20 (44%) | 63 (56%) | 259 (53%) |
| Female | 318 (47%) | 26 (56%) | 80 (44%) | 229 (47%) |
| Age at diagnosis, years | 62 (56-68) | 60 (53-66) | 61 (55-67) | 63 (56-68) |
| 28-59 at diagnosis | 267 (39%) | 23 (50%) | 66 (46%) | 178 (36%) |
| 60-90 at diagnosis | 410 (61%) | 23 (50%) | 77 (54%) | 310 (64%) |
| Surgical status | ||||
| Underwent resection | 235 (35%) | 19 (41%) | 43 (30%) | 173 (36%) |
| Metastatic or unresectable | 442 (65%) | 27 (59%) | 100 (70%) | 315 (64%) |
| History of platinum therapy | ||||
| Received a platinum | 492 (73%) | 43 (94%) | 105 (73%) | 344 (70%) |
| No previous platinum | 185 (27%) | 3 (6%) | 38 (27%) | 144 (30%) |
| Lines of therapy | ||||
| ≥2 (advanced setting) | 410 (61%) | 39 (85%) | 83 (58%) | 288 (59%) |
| 1 (advanced setting) | 267 (39%) | 7 (15%) | 60 (42%) | 200 (41%) |
| Ethnicity or race | ||||
| White | 414 (61%) | 28 (61%) | 77 (54%) | 309 (63%) |
| Hispanic | 21(3%) | 2 (4%) | 8 (6%) | 11 (2%) |
| Black | 16 (2%) | 0 | 4 (3%) | 12 (3%) |
| Asian | 36 (5%) | 1 (2%) | 13 (9%) | 23 (5%) |
| Other | 15 (2%) | 2 (4%) | 2 (1%) | 11 (2%) |
| Not reported | 175 (26%) | 13 (28%) | 39 (27%) | 125 (25%) |
Data are n (%) or median (IQR). Proportions might not sum to 100% as a result of rounding.